Arcutis Biotherapeutics Inc

NASDAQ:ARQT  
20.62
+0.77 (+3.88%)
Products, Regulatory

Arcutis' Roflumilast Foam Demonstrates Clinically Meaningful Results And Patient Quality Of Life Improvements In Phase 2 Seborrheic Dermatitis Study

Published: 03/25/2022 11:40 GMT
Arcutis Biotherapeutics Inc (ARQT) - Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study.
Arcutis - Previously Reported Data Showed Roflumilast Foam Provided Statistically Significant Improvement in Disease Severity, Favorable Safety, Tolerability Profile.